RxDoctor Payments Data

Michelle von der Heyde, APRN

Psychiatric/Mental Health · Miami, FLNPI 1386242402

Payments from drug & device makers

$560in general payments, 2019–2025

Across 22 payments — averaging $25.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$85
  • Seagen Inc.$78
  • Merck$55
  • Bayer$52
  • Regeneron Healthcare Solutions, Inc.$47
  • BTG International Inc.$47
  • plus $196 from 8 others

What the payments were for

  • Food & beverage$48286%
  • Education$7814%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$560 in reported general payments places this provider in the 45th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$5,248
Medicare patients
45
Services billed
92

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib32$507,760
TagrissoOsimertinib Mesylate30$490,691
LenvimaLenvatinib Mesylate19$458,689
RevlimidLenalidomide16$331,847
TruqapCapivasertib13$299,486
KisqaliRibociclib Succinate13$211,874
CalquenceAcalabrutinib Maleate12$184,841
OrgovyxRelugolix28$75,624
EliquisApixaban31$18,084
Abiraterone Acetate21$13,033
Exemestane14$2,191
Hydroxyurea21$774
Letrozole11$376
Prochlorperazine Maleate22$324
Anastrozole27$284

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTagrisso, Truqap, Calquence$26$975,01855 claims
NovartisKisqali$26$211,87413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →